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ABSTRACT In light of the rising prevalence of antimicrobial resistance (AMR) and the slow pace of new
antimicrobial development, there has been increasing interest in the development of adjuvants that
improve or restore the effectiveness of existing drugs. Here, we use a novel small RNA (sRNA) screening
approach to identify genes whose knockdown increases ciprofloxacin (CIP) sensitivity in a resistant strain of
Escherichia coli. 5000 sRNA constructs were initially screened on a gyrA S83L background, ultimately
leading to 30 validated genes whose disruption reduces CIP resistance. This set includes genes involved
in DNA replication, repair, recombination, efflux, and other regulatory systems. Our findings increase un-
derstanding of the functional interactions of DNA Gyrase, and may aid in the development of new thera-
peutic approaches for combating AMR.
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The rapid evolution of antimicrobial resistance (AMR) among bacterial
pathogens and the slow development of new antibiotics have driven the
search for novel approaches to counteract the resistance crisis (Levy and
Marshall 2004; Davies and Davies 2010; Spellberg et al. 2004; Payne
et al. 2007). Recently, re-sensitization of resistant strains to existing
antibiotics has emerged as a promising strategy (Wright 2000; Bassetti
et al. 2008). Compounds that reduce bacterial resistance, and that
thereby restore the effectiveness of existing drugs, are a promising
variety of antibiotic adjuvant (Wright 2016; González-Bello 2017).
Certain b-lactamase inhibitors, for example, restore susceptibility to
cephalosporins by inhibiting degradative enzymes (extended-spectrum
b-lactamases, ESBLs) that are often responsible for resistance (Drawz
and Bonomo 2010; King et al. 2014).
Here, we use a bacterial small RNA (sRNA) screen to identify genes
whose knockdown re-sensitizes DNA gyrase-mediated resistance to the
fluoroquinolone antibiotic ciprofloxacin (CIP). CIP is a synthetic
antibiotic used globally for the treatment of many bacterial infections
(Hooper 1999; Hooper and Rubinstein 2004; Bolon 2011); high-level
resistance is typically conferred by mutations in the gyrA gene, which
encodes one subunit of DNA gyrase, the primary target of quinolones
(Drlica and Zhao 1997; Walsh 2000). The S83L substitution in the
GyrA subunit confers a high level of CIP resistance in E. coli (Bagel
et al. 1999; Bhatnagar andWong 2019). We reasoned that CIP suscep-
tibility might be restored in gyrAmutants by disrupting genes involved
in the function of DNA Gyrase, or by altering cell permeability to CIP.
Bacterial sRNAs are widespread, non-coding RNAmolecules. They
are typically 50-300 nucleotides in size, trans-encoded, with distinct
stem loops as secondary structures (Argaman et al. 2001; Gottesman
2004; Vogel and Sharma 2005, Sharma and Vogel 2009; Yoo et al.
2013). They play prominent roles in bacterial physiology by controlling
gene expression post-transcriptionally. Each sRNA consists of two
important regions. One is the recognition region that regulates
sRNA-mRNA base-pairing through antisense short complementary
base-pairing with the 59 untranslated region (UTR) or translation ini-
tiation region (TIR), and the other is the scaffold (Hfq) region that
stabilizes sRNA-mRNA base-pairing (Møller et al. 2002; Zhang et al.
2002; Storz et al. 2004; Jousselin et al. 2009; Vogel and Luisi 2011;
Holmqvist and Vogel 2013; Vazquez-Anderson and Contreras 2013;
Lee andMoon 2018; Lee et al. 2019). Binding of sRNA tomRNA targets
can reduce gene expression by inhibiting translation or promoting
mRNA degradation.
In eukaryotes, RNA interference (RNAi) is used extensively for
studies of gene function. RNAi mediated gene silencing through short
interfering (siRNA) and short hairpin (shRNA) RNAs has become a
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mainstay in cancer research and is a recognized basis of target validation
and drug development (Silva et al. 2005, 2008; Schlabach et al. 2008;
Scholl et al. 2009). In prokaryotes, comparable use of sRNA as a
genetic tool is promising: proof-of-principle studies have demonstrated
sRNA-mediated knockdown of protein levels, and several successful
screens have been carried out (Nakashima et al. 2006; Meng et al. 2012;
Man et al. 2011; Sharma et al. 2011, 2013). In the context of AMR,
Lee et al. (2011) used a targeted sRNA screen to identify 45 genes whose
knockdown reduced resistance to at least one of seventeen clinically
relevant antibiotics, including essential genes that would be missed in
knockout-driven screening approaches.
In this study, we randomized the antisense sequences of three
naturally occurring sRNAs to generate an sRNA expression librarywith
the potential to target diverse mRNA transcripts. We identified a
number of sRNA sequences that reduce quinolone resistance on a gyrA
S83L background. Further bioinformatic and functional analyses con-
firmed several genes whose down-regulation reduces resistance levels,
and that may thus be promising adjuvant targets.
MATERIALS AND METHODS
Bacterial strains, media and plasmid construction
One shot Top10 E. coli (Invitrogen, F- mcrA D(mrr-hsdRMS-mcrBC),
j80lacZDM15, DlacX74 recA1 araD139 D(ara leu)7697, galU, galK,
rpsL (StrR), endA1, nupG) chemically competent cells were used for
the development of randomizationmethods and for vector maintenance.
For the sRNA screen, a quinolone resistant derivative of E. coli K-12
(MG1655) was generated by gene gorging (Herring 2003). Briefly, a
fragment of gyrA encoding the S83L substitution (via a TCG-.TTG
mutation) and an I-SceI restriction site was generated by megaprimer
PCR (Herring 2003) and cloned into the PCR2.1 vector using TOPO
cloning (Invitrogen). This donor plasmid was co-transformed into
E. coli K-12 (MG1655) along with the mutagenesis plasmid pACBSR.
I-SceI endonuclease and l-red functions encoded on pACBSR were
then induced with arabinose. Potential mutants were plated on LB,
and replica plated to LB+50 mg/ml kanamycin, LB+25 mg/ml chlor-
amphenicol, or LB+25ng/ml ciprofloxacin to identify clones that had
incorporated the S83L substitution and lost the donor and mutagen-
esis plasmids. Successful mutagenesis was confirmed by Sanger
sequencing.
Cultures were grown in Lysogeny broth/agar cultures (LB) (10 g/l
tryptone, 5 g/l yeast extract, 10 g/l NaCl; Bishop) at 37 throughout this
study. LB media supplemented with 100mg/ml ampicillin (Sigma-
Aldrich) was used for plasmid maintenance. Susceptibility assays were
performed using CIP (Sigma-Aldrich) at 100ng/ml.
Randomized library construction
The small RNA expression vectors pBad- DsrA, MicF and Spot42
(Sharma et al. 2011; kindly donated by Yohei Yokobayashi, Okinawa
Institute of Science and Technology) were used as templates for poly-
merase chain reaction (PCR) reactions. Randomized artificial sRNAs
were constructed by incorporating random sequences in the antisense
domains of these sRNAs using PCR primers with degenerate bases
(Figure 1A). The native antisense domains of the sRNA scaffolds were
absent from these constructs. Platinum Pfx polymerase (Invitrogen)
was used to PCR amplify the whole plasmid with a common reverse
primer Sartrev containing 20 degenerate bases and an sRNA specific
forward primer consisting of 10 degenerate bases for randomizing the
antisense domain. The complete list of oligonucleotides used in this
study is provided in Supplemental Material, Table S1.
The PCR amplicon was purified (Bio Basic) and digested using the
DpnI enzyme (New England Biolabs) for 2 hr at 37 to cleave the
methylated template parental DNA. Digested plasmids were phosphor-
ylated using T4 polynucleotide kinase (New England Biolabs) for
20 min at 37. After phosphorylation, the linear DNA was self-ligated
using T4 DNA ligase (New England Biolabs) and incubated at
25 overnight.
Figure 1 A schematic representation for the construc-
tion of the randomized artificial sRNA library. (A) The
antisense domain is randomized with 10-30 random-
ized bases. The randomized bases were incorporated
upstream of the scaffold regions of DsrA, MicF and
Spot42 by PCR amplification of source vectors lacking
the antisense regions (“empty” sRNA). (B) The subse-
quent randomized product was transformed into a gyrA
S83L mutant to obtain a randomized artificial library,
with each clone bearing a novel sRNA construct.
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The consistency of the randomization protocol was first verified in
Top10cells. Subsequently, the randomizedsRNAlibrarywas introduced
into an E. coli gyrA S83Lmutant by transforming chemically competent
cells with the self-ligated PCR amplicons. Transformations were plated
on LB agar supplemented with ampicillin, single colonies were picked,
grown overnight at 37 at 150 rpm with 100mg/ml ampicillin, and
glycerol stocks were prepared in 96 well plates for further screening.
Controls in each of the 96 well plates included gyrA S83L carrying
empty sRNA plasmid and untransformed E. coli MG1655. Libraries
were constructed separately for each of the three expression vectors,
consisting of 5000 transformants in total. 40 plasmids from the
randomized library (roughly equal numbers from each plasmid back-
bone) were extracted and sent for Sanger sequencing to confirm
randomization.
Ciprofloxacin sensitivity screen
In order to identify sRNA constructs that increasedCIP sensitivity, 24 h
growth curves in CIP-containing media were assayed for 5000 gyrA
S83L mutant clones bearing randomized constructs. Cultures were in-
oculated at a 1:100 dilution from glycerol stock cultures and grown
overnight at 37, 150 rpm in LB with 100mg/ml ampicillin for sRNA
plasmid maintenance. For 24 h growth curves, the overnight cultures
were diluted (1:100) in LB supplemented with 100ng/mL CIP, 0.5mM
arabinose, and 100mg/ml ampicillin. Arabinose is required to induce
expression of the sRNA construct. 100 ng/mL CIP was chosen as an
intermediate concentration between the minimum inhibitory con-
centration (MIC) of the WT (30 ng/mL) and the S83L mutant
(600 ng/mL). The OD600 of each culture was measured on a Biotek
ELx808 plate reader every 37 min for 24 h, incubating at 37 with
30 s of shaking every 5 min. Two growth parameters, lag time
and maximum growth rate, were estimated using the program
GrowthRates (Hall et al. 2014). For each well, OD600 at time zero
was used as a well-specific blank.
Clones showing growth repression in the primary CIP sensitivity
screenwere selected for secondary screening in thepresenceandabsence
of CIP (100ng/ml) using similar experimental methods as described
above. Clones whose growth was repressed in the presence of CIP, but
not in LB alone, were selected for further analysis.
Target identification
In order to identify potential targetmRNAs, sRNAvectorswere extract-
ed from CIP-sensitive clones and their sRNA regions were Sanger
sequenced. Putative mRNA targets were identified for the randomized
sRNA sequences using the online software packages IntaRNA (Mann
et al. 2017), Target RNA (Kery et al. 2014) and RNA predator
(Eggenhofer et al. 2011). These web based programs predict hybridiza-
tions between two RNAmolecules, and provide a graphical overview of
the sRNA-mRNA binding interactions (Tjaden 2008; Smith et al. 2010;
Eggenhofer et al. 2011). The resulting target genes were identified and
selected for experimental validation.
Validation for selected targets
Candidate genes whose knockdownmay induce CIP sensitization were
validated experimentally by constructing double mutants, in which the
gyrA S83L mutation was combined with knockout mutations of the
computationally predicted target genes. The knockout mutants were
selected from the Keio mutant collection (Baba et al. 2006), wherein a
kanamycin resistance cassette was used to replace non-essential genes.
The gyrA S83L mutation was introduced by oligonucleotide-mediated
recombineering (Ellis et al. 2001) into the Keio deletion mutants, to
construct each double mutant. A mobilizable derivative of pMA7SacB
was used (Lennen et al. 2015), in which an arabinose-inducible pro-
moter (PBAD) controls expression of the b subunit of l-Red recombi-
nase and the E. coliDammethylase. Dammethylase induction has been
shown to increasemutagenesis efficiencies in E. coli, while reducing off-
target effects, by transiently interfering with the DNA mismatch repair
system (Lennen et al. 2015). The plasmid was introduced into recipient
strains by conjugation using a donor E. coli strain (WM3064) that is
auxotrophic to diaminopimelic acid (DAP) (Dehio and Meyer 1997;
Saltikov and Newman 2003). Recipients (Keio mutants) were cultured
in LB broth supplemented with 30 mg/ml kanamycin and the donor
was cultured in LB supplemented with 0.3 mM DAP and 100 mg/ml
ampicillin (for Red plasmid maintenance). Mating mixtures were spot-
ted on LB agar with 0.3 mM DAP and incubated overnight. Exconju-
gates were selected with 100 mg/ml ampicillin on LB lacking DAP, to
prevent growth of donors. l-Red recombination was performed on
Keio mutants harboring the Red plasmid as previously described
(Lennen et al. 2015) using an oligonucleotide encoding the gyrA
(S83L) mutation (59-AACGCAGCGAGAATGGCTGCGCCATGCGG-
ACGATCGTGTCATAGACCGCCAAGTCACCATGGGGATGGTA-
TTTACCGATTACGTCACCAA-39). A single round of recombination
was carried out to minimize off-target effects. Transformants harboring
the gyrA mutation were selected by plating on LB supplemented with
30mg/ml ciprofloxacin and 30mg/ml kanamycin. The strains were cured
of the l Red plasmid by sacB counterselection by streaking on LB
agar containing 5% sucrose. The gyrA gene of each putative double
n■ Table 1 Randomized sequences of artificial sRNAs constructs. 10-30 randomized bases (bold) were incorporated
upstream of the scaffold regions of DsrA, MicF and Spot42 by PCR amplification of source vectors lacking the antisense
regions (“empty” vectors). All of the sRNAs start from the vector-derived sequence of 5`ACTCGAG (italics). Example
randomized sequences are shown for each construct (2 or 3, as indicated in parentheses)
Scaffold Randomized region
Empty DsrA sequence actcgagcaattttttaagtgcttcttgcttaag
actcgagttgtacctgctttcgatacgactttcatcaattttttaagtgcttcttgcttaag
Example randomized DsrA (3) actcgagttctctcgtcggactgaacgtggagctggaattttttaagtgcttcttgcttaag
actcgaggaattcggaccatgataccactgagtttaattttttaagtgcttcttgcttaag
Empty MicF sequence actcgagcgtcattcatttctgaatgtctg
actcgagtccccttcacgggtgcaacgggccaatggcgtcattcatttctgaatgtctg
Example randomized MicF (3) actcgagctatacagatcatttacaccccgtacatccgtcattcatttctgaatgtctg
actcgagggtagtagactgcgtcattcatttctgaatgtctg
Empty Spot42 sequence actcgagatttggctgaatattttagccgc
actcgagggagggggggatttggctgaatattttagccgc
Example randomized Spot42 (2) actcgagccgtatagaaccacatctgcctgggggggatttggctgaatattttagccgc
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mutant was PCR amplified and Sanger sequenced to verify the
presence of the S83L mutation (PCR primers: Gyrase forward -
59GTAAAACGACGGCCAGTGATGAGCGAC39, Gyrase reverse -
59CGGTACGGTAAGCTTCTTC39).
Ciprofloxacin susceptibility assay
Minimuminhibitoryconcentrations (MIC) forCIPweredetermined for
each of the gyrA S83L/ Keio knockout double mutants using a 96 well
plate assay. Antibiotic concentrationswere started at 125ng/ml, 4ug/ml,
and 8ug/ml for Keio single knockout mutants, double mutants (Keio
single knock out mutant + gyrA S83L), and controls (cybC only and
cybC + gyrA S83L) respectively, andwere diluted in a twofold series and
dispensed with 125ml/well of LB into 96-well plates. The 96 well plates
were incubated overnight at 37, with shaking at 150 rpm. The MIC
was defined as the lowest concentration of antibiotic for which 90%
growth inhibition was visibly observed after overnight culture.
Data availability
Strains and plasmids are available upon request. File S1 contains the
data presented in this manuscript. Supplemental material available at
figshare: https://doi.org/10.25387/g3.7877543.
RESULTS
Randomized sRNA library construction
We generated a library of artificial sRNAs by randomizing the antisense
domain sequences of three native E. coli sRNAs: DsrA, MicF, and
Spot42. We transformed the sRNA library into an E. coli gyrA S83L
mutant and collected a total of 5000 clones, each bearing a plasmid
with an artificial sRNA construct (Figure 1A, B). We arbitrarily isolated
40 clones from the plasmid library and sequenced their sRNA regions
to check for the incorporation of randomized sequences. The sequenc-
ing results confirmed the presence of unique randomized sequences in
Figure 2 Boxplot distributions of CIP-sensitivity phenotypes for 5000 gyrA S83L mutants harboring randomized sRNA plasmid constructs. The
growth rate (A) and lag time (B) distributions are depicted for clones cultured in LB with 600 ng/ml CIP. E. coli MG1655 grown without CIP, and
gyrA S83L mutants bearing empty sRNA plasmids grown with CIP, were used as controls. The boxplots give the median and first and third
quartiles, with whiskers showing either the maximum (minimum) value or 1.5 times the interquartile range of the data, whichever is smaller (larger).
The outliers (528 clones) selected for further investigation have substantial reductions in growth rate and/or increased lag phase.
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each of the engineered sRNA constructs (example sequences are shown
in Table 1).
Ciprofloxacin sensitivity screening
To identify clones with increased susceptibility toward CIP, all 5000
gyrA S83L clones bearing sRNA constructs were grown in LB supple-
mented with 100ng/mL CIP and arabinose to induce sRNA expression.
The MIC of the gyrA S83L mutant is 600ng/ml, so we reasoned that
incubation at this sub-MIC concentration of CIP would be a good
indicator for changes in sensitivity. Controls included wild-type
E. coli MG1655 grown in LB without CIP (median growth rate: 0.06
OD600 /minute and length of lag phase: 41 min), and a gyrA S83L
mutant bearing a non-randomized plasmid grown in LB+CIP (median
growth rate: 0.05 OD600 /minute and length of lag phase: 47.8 min)
(Figure 2). We selected a total of 528 clones exhibiting substantial
reductions in growth rate and/or increased lag phase (outliers from
Figure 2). From the individual sRNA scaffolds, we selected 199 clones
from DsrA (median growth rate: 0.04 OD600 /minute and length of
lag phase: 62.1 min), 231 clones from MicF (median growth rate:
0.04 OD600/minute and length of lag phase: 64.6 min), and 98 clones
from Spot42 (median growth rate: 0.05 OD600/minute and length of
lag phase: 60 min).
We repeated the growth curves of the 528 putatively CIP susceptible
clones in the presence and absence of CIP (Figure 3, Figure S1). This
secondary screen was performed in order to verify the CIP-sensitive
phenotypes and to determine whether or not the growth deficiencies
were specific to CIP; a growth deficit in LB alone would indicate a general
fitness effect of the sRNA, rather than reversal of CIP resistance. From
this secondary screen, we selected 48 clones showing little or no growth
inhibition in LBwithout CIP (Mean growth rate: 0.07 OD600/minute and
length of lag phase: 48.1 min), but whose growth was inhibited in LB
supplemented with CIP (Mean growth rate: 0.02 OD600/minute and
length of lag phase: 85 min).
Identification of target genes
We sequenced the randomized antisense regions of the sRNA plasmids
isolated from the 48 clones exhibiting growth defects specific to the
presence of CIP. Candidate target mRNAs were identified using the
online tools IntaRNA, Target RNA and RNA predator (Mann et al.
2017; Kery et al. 2014; Eggenhofer et al. 2011). These packages predict
target mRNA sites in the E. coli MG1655 transcriptome with the
potential for complementary sRNA interactions. We detected com-
plementary hits for 31/48 randomized sequences (an example of
complementarity between an artificial sRNA and its predicted target
gene (sbmC) is shown in Figure S2). Since these tools identify comple-
mentary matches between short sequences, several sequences were
matched to multiple targets, resulting in a total of 222 potential gene
targets (Table S2). Candidate targets included genes involved in DNA
repair and recombination (recC, recD, recJ, sbmC), the SOS response
and error prone replication (umuC, xseA), transcriptional regulation
(yeeY, mtlR), cell wall division and assembly (zipA, minC), transport
and efflux (emrB, tolQ), two-component regulatory systems (cpxA,
cpxR, ompR, cheB), and chaperone proteins (hybB, dnaK).
Experimental validation of targets
We carried out validation experiments for 36 genes that encoded
potential mRNA targets (Table 2). Since CIP primarily interacts with
DNAGyrase, we focused on putative target genes related to Gyrase and
its functions in DNA replication, repair and recombination. Additional
genes were chosen because of their roles in efflux transport systems,
two-component regulatory systems, transcriptional regulators and as
chaperone proteins (Table 2). For each candidate target gene, the cor-
responding knockout mutant was obtained from the Keio single gene
knockout collection (Baba et al. 2006). The gyrA S83L mutation was
then transferred into the Keio clone byl-Redmutagenesis, generating a
double mutant.
To determine which candidate target genes conferred increased
sensitivity to CIP on the gyrA S83L background, we obtained the
MIC of each double mutant and the corresponding single mutants
(Table S3). Knockout of a pseudogene, cybC, was used as a control
for the effect of the kanamycin cassette present in the Keio clones.
The MIC values of a number of double mutants showed reduced sus-
ceptibility when compared to the cybC+S83L (MIC = 1000ng/ml) dou-
ble mutant. Importantly, for 30 genes, the reduction in CIP resistance
Figure 3 Effects of sRNA expression
on growth rate (OD600/minute) and
length of lag phase (minutes) with
and without CIP. The 48 selected con-
structs showing repression in growth
in the presence of CIP are indicated
in blue.
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was more pronounced on the gyrA S83L background than on the WT
background; these genes fall below the 1:1 line on Figure 4. Inactivation
of these genes thus leads to substantial reductions in gyrA-mediated
CIP resistance. While we did not explicitly account for off-target effects
of the l-Red recombineering used to generate the double mutants, off-
target mutations are unlikely to account for the majority of reductions
in MIC, since every double mutant was generated independently.
Mutants showing a reduction in CIP MIC on the gyrA S83L back-
ground include xseA, tus (double mutant MIC reduction of 16-fold),
sbmC (double mutant MIC reduction of eightfold), tolQ and tolC
(double mutant MIC reduction of 16-fold).
DISCUSSION
We carried out an sRNA screen to identify genes whose knockdown
restores quinolone sensitivity in E. coli. Following an initial screen of
5000 sRNA-bearing clones, and secondary screening of over
500 clones, we found 30 genes whose disruption increases sensitivity
of a gyrA S83L mutant by twofold or more. Our findings expand
knowledge of the genetic interaction network of the essential gene gyrA,
and provide potential targets for the development of antibiotic adju-
vants to restore sensitivity in quinolone resistant pathogens.
Chemical-genetic sensitivity screens have largely used knockout
approaches, whereby a library of knockout mutants is screened for
sensitivity or resistance to an antibiotic at sub-lethal concentrations
(e.g., Tamae et al. 2008; Breidenstein et al. 2008; Fajardo et al. 2008;
Gomez and Neyfakh 2006; Liu et al. 2010). Typically, such screens are
carried out on a wild-type, antibiotic susceptible background, so they
are not well-suited to identifying genes whose knockdown reverses
resistance. Nonetheless, Tamae et al. (2008) did show that knockouts
of five genes recovered from a sensitivity screen (recC, recA, fis, xseA,
tolC; all but fis were also found here) did reduce CIP resistance on a
gyrA mutant background. sRNA screens offer a powerful means for
identifying genetic-background specific effects, since sRNA libraries
can be readily generated in any transformable strain (Sharma et al.
2011, 2013; Lee et al. 2011). Moreover, inducible sRNA constructs
can be used for studying gene functions of essential genes as well as
non-essential genes (Rodrigo et al. 2012), which is not possible with
knockouts. The randomization approach that we have adopted here
(see also Sharma et al. 2011, 2013) is particularly promising, since it
does not require targeted cloning of gene-specific sRNAs. We note a
need for additional efforts to test and refine sRNA scaffolds – it is
unknown, for example, whether different scaffolds differ in the extent
of knockdown achieved for their targets.
It is likely that a larger pool of sRNA clones would be needed to
saturate the genome. It is not straightforward to calculate how many
cloneswouldneed tobe sampled, since eachsRNAmaytargetmore than
onegene. In the limitingcasewhere eachsRNAtargetsonlya single gene,
approximately 13600 sRNA clones would be needed to “hit” 95% of the
4539 genes in the E. coli genome (calculated as 1-exp(-13600/4539);
gene number from ecocyc.org). If each sRNA knocks down more than
one target RNA, however, fewer clones would be needed.
Direct use of sRNAs as therapeutics would require the efficient
expression of a synthetic sRNA construct inside the target bacterial cell.
This would require a competent delivery system, such as phage or a
Figure 4 Fold change in MIC values for 36 knockout mutants on wild-type and gyrA S83L backgrounds. Absolute 1xMIC values for the S83L
mutant and WT are 1000 ng/mL and 30 ng/mL, respectively. The 30/36 mutants that fall below the 1:1 line show reductions in CIP resistance on
the gyrA S83L background but not on the wild-type background.
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conjugative plasmid system. An engineered-phage approach illustrated
by Lu and Collins (2009) expressed the LexA and OmpF proteins from
phageM13. This resulted in reduction in antibiotic resistance evolution
in mice when injected with engineered-phages. Thus, a comparable
approach could be a plausible delivery system for combating resis-
tant bacteria. An alternative strategy would be to identify small
molecules that inhibit the targets identified here. For example, we
showed that inhibition of sbmC reduces CIP resistance by twofold,
and SbmC is a known target of the peptide antibiotic Microcin B17
(Baquero et al. 1995; Collin et al. 2011). Thus, sRNA-mediated tar-
get discovery may be an efficient option for generating prospects for
novel therapeutics.
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